These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8853773)

  • 1. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome.
    Tebano MT; Traversa G; Da Cas R; Loizzo A
    Aliment Pharmacol Ther; 1996 Aug; 10(4):659-63. PubMed ID: 8853773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
    Ransford RA; Langman MJ
    Gut; 2002 Oct; 51(4):536-9. PubMed ID: 12235076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine in childhood inflammatory bowel disease.
    Barden L; Lipson A; Pert P; Walker-Smith JA
    Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
    Kovács A
    Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
    Kreisel W; Wolf LM; Grotz W; Grieshaber M
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia.
    Selinger CP; Kemp A; Leong RW
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):329-34. PubMed ID: 24490626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [5-ASA versus sulfasalazine].
    Varela E
    Acta Gastroenterol Latinoam; 1994; 25(5):317-9. PubMed ID: 7785405
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
    Pearce CB; Duncan HD; Timmis L; Green JR
    Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?
    van Bodegraven AA; Mulder CJ
    World J Gastroenterol; 2006 Oct; 12(38):6115-23. PubMed ID: 17036381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: the use of mesalazine in inflammatory bowel disease.
    Bergman R; Parkes M
    Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.